Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?

Executive Summary

The US FDA approved Teva's fremanezumab dosed monthly and quarterly versus Amgen's monthly Aimovig, and will launch at the same price. However, it's packaged as a pre-filled syringe instead of an autoinjector, has a higher rate of injection site reactions and it may launch alongside Lilly's Emgality.

You may also be interested in...



Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market

After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.

Teva’s Ajovy Claims 28%-30% New Prescription Share In Competitive CGRP Race

The company said it has captured a roughly 28%-30% share of new prescriptions in the CGRP market with the initial launch of Ajovy, a key future growth driver to offset declining Copaxone sales.

No More Deal? Novartis, Amgen Trade Lawsuits Over Aimovig Agreements

Novartis wants a federal judge to stop Amgen from terminating the companies' agreements around potential migraine blockbuster Aimovig, in which it claims to have invested $870m to date. Amgen wants to go to trial, letting a jury decide whether it can end the partnership – and win damages.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel